Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) for the reporting period of June 6, 2012, covering an event that occurred on June 5, 2012. The company is a Delaware corporation focused on stem cell therapies.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
On June 5, 2012, the Emory University Institutional Review Board (IRB) approved an amendment to the Company's ongoing Phase I clinical trial. This trial evaluates the Company's spinal cord stem cells for the treatment of amyotrophic lateral sclerosis (ALS). The amended protocol had previously received approval from the U.S. Food and Drug Administration (FDA), pending this IRB approval.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of general risks. The primary focus is the regulatory milestone achieved for the ALS clinical trial.
Investor Verification Checklist
- Verify the specific details of the Phase I trial amendment approved by the Emory University IRB.
- Confirm the status of the FDA approval for the amended protocol referenced in the filing.
- Review the attached press release (Exhibit 99.01) for further details on the clinical trial timeline.
- Note that the registrant name in the filing is Neuralstem, Inc., which differs from the metadata provided.